Torrent Pharma posts 51% revenue jump as integration synergies lift margins
Torrent Pharma's Q2 revenue rose 51% and operating EBITDA 54%, with management expecting better H2 margins and a gradual recovery in JB growth.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Torrent Pharma reported Q2 revenue up 51% and operating EBITDA up 54%, according to TradingView. Integration temporarily weighed on JB's international sales. Cost synergies are running ahead of plan, and management expects margins to improve in the second half and JB growth to recover gradually.
why it matters
For investors the signal is that integration is delivering savings faster than planned, even as international sales face a temporary drag. The H2 margin outlook is the key variable to watch. The story concerns a single company, so broader market impact is limited.
market impact
Torrent Pharma shares: strong revenue growth and margin outlook support earnings expectations
tags
instruments
sources
- TORNTPHARM: Revenue and EBITDA surged; integration synergies support a gradual recovery and margin gains — TradingView, 23 October 2026 at 16:52 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗